Sixun Yu

Dr. Sixun Yu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2020 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
TYTao Yang
Tao Yang
ZNZheng Nie
Zheng Nie
HSHaifeng Shu
Haifeng Shu
YKYongqin Kuang
Yongqin Kuang
XCXin Chen
Xin Chen
HLHuiying Liu
Huiying Liu
Using behavioral, pharmacological, and molecular methods, lots of studies reveal that depression is closely related to the abnormal neural plasticity processes occurring in the prefrontal cortex and limbic system such as the hippocampus and amygdala. Meanwhile, functions of the brain-derived neurotrophic factor (BDNF) and the other neurotrophins in the pathogenesis of depression are well known. The maladaptive neuroplastic in depression may be related to alterations in the levels of neurotrophic factors, which play a central role in plasticity. Enhancement of neurotrophic factors signaling has great potential in therapy for depression. This review highlights the relevance of neurotrophic factors mediated neural plasticity and pathophysiology of depression. These studies reviewed here may suggest new possible targets for antidepressant drugs such as neurotrophins, their receptors, and relevant signaling pathways, and agents facilitating the activation of gene expression and increasing the transcription of neurotrophic factors in the brain.

26 August 2024 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
ZQZhichuang Qu
Zhichuang Qu
JLJuan Luo
Juan Luo
ZLZheng Li
Zheng Li
RYRong Yang
Rong Yang
JZJiaxi Zhao
Jiaxi Zhao
HSHai-Feng Shu
Hai-Feng Shu
The blood–brain barrier is known to consist of a variety of cells and complex inter-cellular junctions that protect the vulnerable brain from neurotoxic compounds; however, it also complicates the pharmacological treatment of central nervous system disorders as most drugs are unable to penetrate the blood–brain barrier on the basis of their own structural properties. This dramatically diminished the therapeutic effect of the drug and compromised its biosafety. In response, a number of drugs are often delivered to brain lesions in invasive ways that bypass the obstruction of the blood–brain barrier, such as subdural administration, intrathecal administration, and convection-enhanced delivery. Nevertheless, these intrusive strategies introduce the risk of brain injury, limiting their clinical application. In recent years, the intensive development of nanomaterials science and the interdisciplinary convergence of medical engineering have brought light to the penetration of the blood–brain barrier for brain-targeted drugs. In this paper, we extensively discuss the limitations of the blood–brain barrier on drug delivery and non-invasive brain-targeted strategies such as nanomedicine and blood–brain barrier disruption. In the meantime, we analyze their strengths and limitations and provide outlooks on the further development of brain-targeted drug delivery systems.

22 May 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JXJing Xu
Jing Xu
DSDanyi Shen
Danyi Shen
YWYao Wang
Yao Wang
XHXingyue Han
Xingyue Han
XDXinning Dong
Xinning Dong
SYSixun Yu
Sixun Yu

15 September 2023 in Frontiers in Neurology
Verified
Journal Article
Open access
RYRong Yang
Rong Yang
ZLZheng Li
Zheng Li
JXJing Xu
Jing Xu
JLJuan Luo
Juan Luo
ZQZhichuang Qu
Zhichuang Qu
HSHai-Feng Shu
Hai-Feng Shu
Hypoxia is characterized by low oxygen levels in the body or environment, resulting in various physiological and pathological changes. The brain, which has the highest oxygen consumption of any organ, is particularly susceptible to hypoxic injury. Exposure to low-pressure hypoxic environments can cause irreversible brain damage. Hypoxia can occur in healthy individuals at high altitudes or in pathological conditions such as trauma, stroke, inflammation, and autoimmune and neurodegenerative diseases, leading to severe brain damage and impairments in cognitive, learning, and memory functions. Exosomes may play a role in the mechanisms of hypoxic injury and adaptation and are a current focus of research. Investigating changes in exosomes in the central nervous system under hypoxic conditions may aid in preventing secondary damage caused by hypoxia. This paper provides a brief overview of central nervous system injury resulting from hypoxia, and aimed to conduct a comprehensive literature review to assess the pathophysio-logical impact of exosomes on the central nervous system under hypoxic conditions.

2 December 2024 in NeuroReport
Verified
Journal Article
Closed access
XDXinning Dong
Xinning Dong
JXJing Xu
Jing Xu
KDKejun Du
Kejun Du
XCXin Chen
Xin Chen
HSHaifeng Shu
Haifeng Shu
SYSixun Yu
Sixun Yu
This study aimed to examine reticulon 4 (RTN4), neurite outgrowth inhibitor protein expression that changes in high-altitude traumatic brain injury (HA-TBI) and affects on blood–brain barrier’s (BBB) function. C57BL/6J 6–8-week-old male mice were used for TBI model induction and randomized into the normal altitude group and the 5000-m high-altitude (HA) group, each group was divided into control (C) and 8h/12h/24h/48h-TBI according to different times post-TBI. Brain water content (BWC) and modified Neurological Severity Score were measured, RTN4 and autophagy-related indexes (Beclin1, LC3B, and SQSTM1/p62) were detected by western blot, immunofluorescence technique, and PCR in peri-injury cortical tissues. The expression of NgR1, Lingo-1, TROY, P75, PirB, S1PR2, and RhoA receptors’ downstream of RTN4 was detected by PCR. HA-TBI caused increased neurological deficits including motor, sensory, balance and reflex deficits, increased BWC, earlier peak RTN4 expression and a longer duration of high expression in peri-injury cortical tissues, and enhanced levels of Beclin1, LC3B, and SQSTM1/p62 to varying degrees. Concurrently, the transcription of S1PR2 and PirB, the main signaling molecules downstream of RTN4, was significantly increased. In HA-TBI’s early stages, the increased RTN4 may regulate enhanced autophagic initiation and impaired autolysosome degradation in vascular endothelial cells via S1PR2 receptor activation, thereby reducing BBB function. This suggests that autophagy could be a new target using RTN4 intervention as a clinical HA-TBI mechanism.

30 July 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
JXJing Xu
Jing Xu
XDXinning Dong
Xinning Dong
MYMu Yuan
Mu Yuan
XCXin Chen
Xin Chen
HSHai-Feng Shu
Hai-Feng Shu
SYSixun Yu
Sixun Yu
Ferroptosis is a distinctive form of regulated cell death that is closely associated with various neurodegenerative disorders. In recent years, an increasing number of studies have demonstrated the crucial role of ferroptosis in the development and progression of epilepsy. Firstly, this article will review the existing research on the specific biological mechanism of ferroptosis in nerve injury, particularly in epilepsy, encompassing iron metabolism disorders and alterations in the expression of ferroptosis-related proteins. Secondly, with regards to treatment, this article will explore the application of ferroptosis inhibitors in antiepileptic therapy and their potential therapeutic effects. Additionally, it will focus on investigating the interaction between ferroptosis and existing antiepileptic drugs as well as the potential impact of strategies regulating ferroptosis on epilepsy treatment. Finally, we will evaluate both the progress made and limitations encountered in current research while proposing possible future directions for further exploration at the intersection of ferroptosis and epilepsy fields. These studies not only contribute to a better understanding of epileptic pathological mechanisms but also hold promise for providing novel insights and strategies for treating epilepsy.